The plasma cell signature in autoimmune disease

Arthritis and Rheumatology

Volumn 66, Issue 1, 2014, Pages 173-184

  Streicher, Katie ^a   Morehouse, Christopher A ^a   Groves, Christopher J ^a   Rajan, Bhargavi ^a   Pilataxi, Fernanda ^a   Lehmann, Kim P ^a   Brohawn, Philip Z ^a   Higgs, Brandon W ^a   McKeever, Kathleen ^a   Greenberg, Steven A ^b   Fiorentino, David ^c   Richman, Laura K ^a   Jallal, Bahija ^a   Herbst, Ronald ^a   Yao, Yihong ^a   Ranade, Koustubh ^a  

^a Brigham and Women's Hospital Harvard Medical School ^*  (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL MATURATION ANTIGEN; CD19 ANTIBODY; COLLAGEN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN HEAVY CONSTANT ALPHA 1; IMMUNOGLOBULIN J CHAIN; IMMUNOGLOBULIN J POLYPEPTIDE LINKER FOR IMMUNOGLOBULIN ALPHA AND MU; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN KAPPA CONSTANT IMMUNOGLOBULIN KAPPA CHAIN V I REGION; IMMUNOGLOBULIN KAPPA VARIABLE 4 1; MEDI 551; MONOCLONAL ANTIBODY; PLACEBO; UNCLASSIFIED DRUG; AUTOANTIBODY; IMMUNOGLOBULIN; SNC73 PROTEIN, HUMAN; TNFRSF17 PROTEIN, HUMAN; TRANSCRIPTOME;

ARTICLE; ASTHMA; AUTOIMMUNE DISEASE; BLOOD LEVEL; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE ESCALATION; EX VIVO STUDY; GENE EXPRESSION PROFILING; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INCLUSION BODY MYOSITIS; MICROARRAY ANALYSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMA CELL; POLYMYOSITIS; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SCLERODERMA; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TISSUE LEVEL; TREATMENT RESPONSE; BIOSYNTHESIS; GENETICS; METABOLISM; TISSUE MICROARRAY;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; B-CELL MATURATION ANTIGEN; HUMANS; IMMUNOGLOBULIN J-CHAINS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULINS; PLASMA CELLS; SCLERODERMA, SYSTEMIC; TISSUE ARRAY ANALYSIS; TRANSCRIPTOME;

EID: 84897019053     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38194     Document Type: Article

References (41)

1. Dorner T, Jacobi AM, Lipsky PE. B cells in autoimmunity. Arthritis Res Ther 2009;11:247.
2. Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012;366:2008-16.
3. Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tightskin mouse. J Clin Invest 2002;109:1453-62. (Pubitemid 34596171)
4. Tedder TF, Poe JC, Fujimoto M, Haas KM, Sato S. The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: systemic sclerosis as a model system. Curr Dir Autoimmun 2005;8:55-90.
5. Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 2010;237:264-83.
6. Dilillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, Haas KM, et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 2008;180:361-71.
7. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006;6:394-403.
8. Edwards JC, Cambridge G, Leandro MJ. B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol 2006;20:915-28. (Pubitemid 44382384)
9. Ramos-Casals M, Sanz I, Bosch X, Stone JH, Khamashta MA. B-cell-depleting therapy in systemic lupus erythematosus. Am J Med 2012;125:327-36.
10. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al, for the HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-88. (Pubitemid 351240747)
11. Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008;63:395-400. (Pubitemid 351499869)
12. Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011;378:1779-87.
13. Klotz L, Meuth SG, Wiendl H. Immune mechanisms of new therapeutic strategies in multiple sclerosis-a focus on alemtuzumab. Clin Immunol 2012;142:25-30.
14. Dorner T, Burmester GR. New approaches of B-cell-directed therapy: beyond rituximab. Curr Opin Rheumatol 2008;20:263-8. (Pubitemid 351483314)
15. Cooper LJ, Al-Kadhimi Z, DiGiusto D, Kalos M, Colcher D, Raubitschek A, et al. Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. Blood Cells Mol Dis 2004;33:83-9. (Pubitemid 38829603)
16. Sato S, Steeber DA, Tedder TF. The CD19 signal transduction molecule is a response regulator of B-lymphocyte differentiation. Proc Natl Acad Sci U S A 1995;92:11558-62.
17. Sato S, Steeber DA, Jansen PJ, Tedder TF. CD19 expression levels regulate B lymphocyte development: human CD19 restores normal function in mice lacking endogenous CD19. J Immunol 1997;157:4371-8.
18. Tedder TF, Inaoki M, Sato S. The CD19/21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 1997;6:107-18. (Pubitemid 27145556)
19. Fujimoto M, Fujimoto Y, Poe JC, Jansen PJ, Lowell CA, De-Franco AL, et al. CD19 regulates Src-family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 2000;13:47-57.
20. Engel P, Zhou LJ, Ord DC, Sato S, Koller B, Tedder TF. Abnormal B lymphocyte development, activation and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 1995;3:39-50.
21. Rickert RC, Rajewsky K, Roes J. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature 1995;376:352-5.
22. Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000;165:6635-43.
23. Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008;4:557-67.
24. Tedder TF. CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol 2009;5:572-7.
25. Owczarczyk K, Lal P, Abbas AR, Wolslegel K, Holweg C, Dummer W, et al. A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. Sci Transl Med 2011;3: ra92-101.
26. Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M, et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther 2010;335:213-22.
27. Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011;70:2029-36.
28. R Development Core Team. R: a language and environment for statistical computing: version 2.11.1. Vienna, Austria: R Foundation for Statistical Computing; 2011.
29. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
30. Jimenez SA, Hitraya E, Varga J. Pathogenesis of scleroderma: collagen. Rheum Dis Clin North Am 1996;22:647-74.
31. Martin P, Teodoro WR, Velosa AP, De Morais J, Carrasco S, Christmann RB, et al. Abnormal collagen V deposition in dermis correlates with skin thickening and disease activity in systemic sclerosis. Autoimmun Rev 2012;11:827-35.
32. Higgs BW, Zhu W, Richman L, Fiorentino DF, Greenberg SA, Jallal B, et al. Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients. Int J Rheum Dis 2012;15:25-35.
33. Wong D, Kea B, Pesich R, Higgs BW, Zhu W, Brown P, et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One 2012;7:e29161.
34. Hiepe F, Hoyer B, Alexander T, Taddeo A, Voll R, Radbruch A. Therapeutic inhibition of proteasomes in systemic lupus erythematosus. J Transl Med 2011;9 Suppl 2:I9.
35. Verrecchia F, Laboureau J, Verola O, Roos N, Porcher R, Bruneval P, et al. Skin involvement in scleroderma-where histological and clinical scores meet. Rheumatology (Oxford) 2007;46:833-41. (Pubitemid 47061718)
36. Fleischmajer R, Gay S, Meigel WN, Perlish JS. Collagen in the cellular and fibrotic stages of scleroderma. Arthritis Rheum 1978;21:418-28. (Pubitemid 9126679)
37. Liu T, Zhang J. Detection of V, III, and I type collagens of dermal tissues in skin lesions of patients with systemic sclerosis and its implication. J Huazhong Univ Sci Technolog Med Sci 2008;28:599-603.
38. Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, Connolly MK, et al. Molecular subsets in the gene expression signatures of scleroderma skin. Plos One 2008;3:e2696.
39. Pendergrass SA, Lemaire R, Francis IP, Mahoney JM, Lafyatis R, Whitfield ML. Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol 2012;132:1363-73.
40. Coca A, Sanz I. Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjögren's syndrome. Curr Opin Rheumatol 2012;24:451-6.
41. Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008;14:748-55. (Pubitemid 351951516)